247 related articles for article (PubMed ID: 30912151)
1. A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia.
Kohli U; Aziz Z; Beaser AD; Nayak HM
Pacing Clin Electrophysiol; 2019 Aug; 42(8):1146-1154. PubMed ID: 30912151
[TBL] [Abstract][Full Text] [Related]
2. Ventricular arrhythmia suppression with ivabradine in a patient with catecholaminergic polymorphic ventricular tachycardia refractory to nadolol, flecainide, and sympathectomy.
Kohli U; Aziz Z; Beaser AD; Nayak HM
Pacing Clin Electrophysiol; 2020 May; 43(5):527-533. PubMed ID: 32259298
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
[TBL] [Abstract][Full Text] [Related]
4. Insights on the mechanism of flecainide in catecholaminergic polymorphic ventricular tachycardia.
Davidson R; Medeiros M
J Med Life; 2023 Aug; 16(8):1294-1296. PubMed ID: 38024821
[TBL] [Abstract][Full Text] [Related]
5. Exon 3 deletion of RYR2 encoding cardiac ryanodine receptor is associated with left ventricular non-compaction.
Ohno S; Omura M; Kawamura M; Kimura H; Itoh H; Makiyama T; Ushinohama H; Makita N; Horie M
Europace; 2014 Nov; 16(11):1646-54. PubMed ID: 24394973
[TBL] [Abstract][Full Text] [Related]
6. Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation.
Nozaki Y; Kato Y; Uike K; Yamamura K; Kikuchi M; Yasuda M; Ohno S; Horie M; Murayama T; Kurebayashi N; Horigome H
Circ J; 2020 Jan; 84(2):226-234. PubMed ID: 31875585
[TBL] [Abstract][Full Text] [Related]
7. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
[TBL] [Abstract][Full Text] [Related]
8. Exon 3 deletion of ryanodine receptor causes left ventricular noncompaction, worsening catecholaminergic polymorphic ventricular tachycardia, and sudden cardiac arrest.
Campbell MJ; Czosek RJ; Hinton RB; Miller EM
Am J Med Genet A; 2015 Sep; 167A(9):2197-200. PubMed ID: 26018045
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
Vaksmann G; Klug D
Pacing Clin Electrophysiol; 2018 Oct; 41(10):1378-1380. PubMed ID: 29989676
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
[TBL] [Abstract][Full Text] [Related]
11. Flecainide in patient with aggressive catecholaminergic polymorphic ventricular tachycardia due to novel RYR2 mutation.
Wangüemert-Pérez F; Ruiz-Hernández PM; Campuzano O; Caballero-Dorta E; Bosch C; Brugada J; Brugada R
Minerva Cardioangiol; 2014 Aug; 62(4):363-6. PubMed ID: 25012103
[No Abstract] [Full Text] [Related]
12. Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia.
Wangüemert Pérez F; Hernández Afonso JS; Groba Marco MDV; Caballero Dorta E; Álvarez Acosta L; Campuzano Larrea O; Pérez G; Brugada Terradellas J; Brugada Terradellas R
Rev Esp Cardiol (Engl Ed); 2018 Mar; 71(3):185-191. PubMed ID: 28789916
[TBL] [Abstract][Full Text] [Related]
13. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B
J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944
[TBL] [Abstract][Full Text] [Related]
14. Current management of inherited arrhythmia syndromes associated with the cardiac ryanodine receptor.
Przybylski R; Abrams DJ
Curr Opin Cardiol; 2023 Jul; 38(4):390-395. PubMed ID: 37016946
[TBL] [Abstract][Full Text] [Related]
15. Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene.
Nof E; Belhassen B; Arad M; Bhuiyan ZA; Antzelevitch C; Rosso R; Fogelman R; Luria D; El-Ani D; Mannens MM; Viskin S; Eldar M; Wilde AA; Glikson M
Heart Rhythm; 2011 Oct; 8(10):1546-52. PubMed ID: 21699856
[TBL] [Abstract][Full Text] [Related]
16. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.
Bannister ML; Thomas NL; Sikkel MB; Mukherjee S; Maxwell C; MacLeod KT; George CH; Williams AJ
Circ Res; 2015 Apr; 116(8):1324-35. PubMed ID: 25648700
[TBL] [Abstract][Full Text] [Related]
17. Catecholaminergic polymorphic ventricular tachycardia: a model for genotype-specific therapy.
Roston TM; Van Petegem F; Sanatani S
Curr Opin Cardiol; 2017 Jan; 32(1):78-85. PubMed ID: 27861184
[TBL] [Abstract][Full Text] [Related]
18. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
Watanabe H; van der Werf C; Roses-Noguer F; Adler A; Sumitomo N; Veltmann C; Rosso R; Bhuiyan ZA; Bikker H; Kannankeril PJ; Horie M; Minamino T; Viskin S; Knollmann BC; Till J; Wilde AA
Heart Rhythm; 2013 Apr; 10(4):542-7. PubMed ID: 23286974
[TBL] [Abstract][Full Text] [Related]
19. Trans-2,3-enoyl-CoA reductase-like-related catecholaminergic polymorphic ventricular tachycardia with regular ventricular tachycardia and response to flecainide.
Ebrahim MA; Alkhabbaz AA; Albash B; AlSayegh AH; Webster G
J Cardiovasc Electrophysiol; 2023 Sep; 34(9):1996-2001. PubMed ID: 37473425
[TBL] [Abstract][Full Text] [Related]
20. A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child.
Duan H; Lu Y; Yan S; Qiao L; Hua Y; Li Y; Zhou K; Wang C
Medicine (Baltimore); 2018 Apr; 97(16):e0368. PubMed ID: 29668588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]